Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Gene therapy reverses sickle cell phenotype in small study

Esrick EB et al. ASH 2018, Abstract 1023

Publish date:: December 24, 2018

Key clinical point: Gene therapy to induce the fetal form of hemoglobin reversed the symptoms of sickle cell disease in an adult patient.

Major finding: During 6 months of follow-up the patient did not experience sickle cell disease–related pain, respiratory events, or neurologic events, and did not have anemia.

Study details: A first-in-human study in seven adults with sickle cell disease.

Disclosures: Dr. Esrick reported receiving honoraria from Bluebird Bio, maker of the short hairpin RNA construct used in the trial.

Read the article here.

Citation:

Esrick EB et al. ASH 2018, Abstract 1023.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Anemia

Emotions, worse attention linked to pain-related health care use SCD,

Oxidatative stress-related genetic variant tied to stroke risk in sickle cell patients,

Genetic variants may predict stroke in some adult SCD populations,

Severe COVID-19 may lower hemoglobin levels,

Low plasma sodium levels can predict complications in acute painful episodes of SCD,